GSK plc (NYSE:GSK) Shares Purchased by AIMZ Investment Advisors LLC

AIMZ Investment Advisors LLC boosted its holdings in shares of GSK plc (NYSE:GSK) by 1.1% in the 4th quarter, Holdings Channel reports. The fund owned 62,531 shares of the pharmaceutical company’s stock after acquiring an additional 666 shares during the quarter. AIMZ Investment Advisors LLC’s holdings in GSK were worth $2,115,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Sunbelt Securities Inc. increased its holdings in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Indiana Trust & Investment Management Co grew its holdings in GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after buying an additional 500 shares in the last quarter. Crews Bank & Trust acquired a new stake in shares of GSK in the 4th quarter worth $26,000. ST Germain D J Co. Inc. raised its holdings in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares during the period. Finally, Sierra Ocean LLC acquired a new position in shares of GSK during the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Ratings Changes

GSK has been the subject of several recent analyst reports. Morgan Stanley assumed coverage on shares of GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. Based on data from MarketBeat, GSK has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Down 0.2 %

NYSE:GSK opened at $37.33 on Friday. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The stock’s fifty day moving average is $34.91 and its two-hundred day moving average is $37.30. The stock has a market capitalization of $77.36 billion, a price-to-earnings ratio of 23.47, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Research analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be issued a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.21%. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.